Market Overview

Cohen Milstein Sellers & Toll PLLC Announces Investigation of Rockwell Medical, Inc.

Share:

Cohen Milstein Sellers & Toll PLLC is conducting an investigation to
determine whether Rockwell Medical, Inc. ("Rockwell" or the "Company")
and certain of its officers and directors made false and misleading
statements and/or omissions in violation of Sections 10(b) and 20(a) of
the Securities Exchange Act of 1934.

A class action lawsuit was filed in the U.S. District Court for the
Eastern District of New York by another law firm on behalf of purchasers
of the common stock of Rockwell Medical, Inc. (NASDAQ:RMTI) between
March 16, 2018 and June 26, 2018, inclusive (the "Class Period").

The Centers for Medicare and Medicaid Services ("CMS") denied Rockwell's
request for a separate reimbursement of the Company's lead product,
Triferic, an iron maintenance therapy for patients who lose iron during
dialysis. The complaint alleges that Rockwell and certain of its
officers and directors ("Defendants") misrepresented and/or failed to
disclose that: (1) Rockwell was aware that CMS would not pursue
Rockwell's proposal for separate reimbursement for Triferic; (2) the
Company's first quarter 2018 Form 10-Q misstated estimate reserves; (3)
there was a material weakness in Rockwell's internal controls over
financial reporting; (4) Rockwell's internal controls over financial
reporting were ineffective during the Class Period; (5) Defendant Robert
L. Chioini, former Rockwell CEO, withheld material information regarding
Triferic from Rockwell's auditor, corporate counsel and five independent
directors of the Board; and (6) as a result, Defendants' statements
about the Company's business, operations and prospects were materially
false and misleading and/or lacked reasonable bases at all relevant
times.

On May 22, 2018, Rockwell announced the termination of CEO Chioini,
effective immediately, and the appointment of a Special Transition
Committee to oversee Rockwell's day-to-day operations. Chioini refused
to accept his firing, and on May 23, 2018, filed a Form 8-K and issued a
press release alleging that five members of the board orchestrated his
ouster after he and CFO Thomas E. Klema hired outside counsel to
investigate allegations in a shareholder demand letter accusing the
directors of breach of fiduciary duty.

On June 27, 2018, Rockwell announced the resignation of its auditor
Plante & Moran, PLLC, effective immediately. In a letter explaining its
decision, Plante & Moran stated:

We have been made aware of the attached e-mail received by Rockwell
Medical, Inc. (Rockwell) on March 27, 2018 in connection with its
ongoing pursuit of Triferic special reimbursement status. This e-mail
was not disclosed to us in the course of our review procedures related
to the financial statements for the quarter ended March 31, 2018 (Q1)
included in Rockwell's form 10Q filed on May 15, 2018. This e-mail and
its contents are inconsistent with representations made to us by
Rockwell, orally and in writing, in connection with our review
procedures.

The price of Rockwell Medical fell from $5.26 on June 26, 2018, to $4.52
on June 27, and closed at $4.41 on June 28.

Cohen Milstein encourages all investors who purchased Rockwell Medical
common stock between March 16, 2018 and June 26, 2018, or former
employees with information concerning this matter to contact the firm.

If you are a Rockwell shareholder and would like to discuss your right
to recover for your economic loss, you may, without any cost or
obligation, call Cohen Milstein's Managing Partner, Steven
J. Toll
at (888) 240-0775 or (202) 408-4600, or email him at stoll@cohenmilstein.com.
If you wish to serve as lead plaintiff, you must move the Court no later
than September 25, 2018 to request appointment. Any member of the
proposed class may retain Cohen Milstein or other attorneys to serve as
your counsel in this action, or you may do nothing and remain an absent
class member.

Cohen Milstein has significant experience in prosecuting investor class
actions and actions involving securities fraud, and is active in major
litigation pending in federal and state courts throughout the nation.
Cohen Milstein has taken a lead role in numerous important cases on
behalf of defrauded investors, and has been responsible for a number of
outstanding recoveries which, in the aggregate, total billions of
dollars. Prior results do not guarantee a similar outcome. For more
information visit www.cohenmilstein.com.

If you have any questions about this notice or the action, or with
regard to your rights, please contact either of the following:

Steven
J. Toll, Esq.

Robin Bleiweis
Cohen Milstein Sellers & Toll
PLLC
1100 New York Avenue, N.W.
Fifth Floor
Washington,
D.C. 20005
Telephone: (888) 240-0775 or (202) 408-4600
Email: stoll@cohenmilstein.com;
rbleiweis@cohenmilstein.com

Attorney Advertising

View Comments and Join the Discussion!